<DOC>
	<DOCNO>NCT01001494</DOCNO>
	<brief_summary>The main purpose study assess long term bronchodilator efficacy , safety tolerability inhale aclidinium bromide two dose level compare placebo COPD patient benefit product disease-related health status , COPD symptoms COPD exacerbation .</brief_summary>
	<brief_title>Efficacy Safety Aclidinium Bromide Two Dose Levels Versus Placebo Administered Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Adult male female patient age ≥40 stable moderate severe COPD ( GOLD guideline ) . Postsalbutamol ( FEV1 ) &lt; 80 % ≥30 % predict normal value Postsalbutamol FEV1/FVC &lt; 70 % . Current exsmokers ≥10 packyears . Patients history current diagnosis asthma . No evidence exacerbation within 6 week prior screen visit . No evidence clinically significant respiratory and/or cardiovascular condition laboratory abnormality . No contraindication use anticholinergic drug know symptomatic prostatic hypertrophy , bladder neck obstruction narrowangle glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>antimuscarinic</keyword>
	<keyword>COPD</keyword>
</DOC>